Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: Clin Cancer Res. 2009 Nov 10;15(22):6800–6809. doi: 10.1158/1078-0432.CCR-09-0312

Figure 3. Immunohistochemistochemical validation of protein expression in VLRWT.

Figure 3

A. Immunohistochemical analysis for HMGA2: All four cluster 1 tumors were negative (left); all seven tumors within clusters 2 were immunoreactive for HMGA2 in greater than 10% of the cells.

B. Immunohistochemical analysis for PDGFRa: All four cluster 1 tumors showed immunoreactivity in fewer than 10% of cells (left); of seven cluster 2 tumors, fewer than 10% of the cells were immunoreactive in three tumors, and greater than 10% of the cells were immunoreactive in four tumors (right).

C. Immunohistochemical analysis for WT-1: All four cluster 1 tumors were immunoreactive for WT1 in greater than 10% of the cells (left); of seven cluster 2 tumors, five showed fewer than 10% of the cells to be positive and two showed greater than 10% of the cells positive (right).

D. Immunohistochemical analysis for PAX8: All four cluster 1 tumors showed greater than 80% of the cells to be immunoreactive for PAX8; of six evaluable cluster 2 tumors, all showed greater than 10% of the cells to be immunoreactive (right).